Zenith DrugsShare price, financial results, shareholding and management
- Market cap
- ₹72 cr
- Stock P/E
- 18.3peers 19.1
- Book value
- ₹42.8
- Price to book
- 0.98
- EV / operating profit
- 10.4
- Market cap to sales
- 0.42
- ROCE · FY26
- 8.9%
- ROE · FY26
- 5.5%
- ROE, 3-year average
- 13.9%
- Operating margin · FY26
- 7.1%peers 10.2%
- Sales growth, 3 years
- 14.5%
- Profit growth, 3 years
- -7.6%
- Debt to equity
- 0.75peers 0.34
- Borrowings
- ₹55.1 cr
- Interest cover
- 2.0×
- Cash from business / op. profit
- 73%
- Debtor days
- 156
- Pledged
- 0.00%
- Promoter holding
- 69.98%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 1,435
- 52-week high / low
- ₹60 / ₹33
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Zenith Drugs share price chart
Close on 17 Nov 2026 · 0.00% on the day · Vol 16,800
Daily prices to 17 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 17 Nov 2026
- 1 month
- +3.4%
- 3 months
- -6.7%
- 6 months
- +7.7%
- 1 year
- -22.3%
- Since IPO
- -46.8%
- Traded a day, 20 days
- ₹0.02 cr
- Taken for delivery
- 88%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +28% | -45% |
| 3 years, a year | +15% | -8% |
| Latest half, H2 FY26 | +42% | +12% |
Zenith Drugs revenue and profit growth
Half-yearly results · Profit and lossSales have grown steadily. Last year profit fell even as sales rose, so the company kept less from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.
Zenith Drugs half-yearly results
SME companies report every six months · ₹ crore
| H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|
| Sales | 69 | 62 | 68 | 65.63 | 78.22 | 93 |
| Expenses | 58 | 56 | 61 | 58.83 | 72.05 | 87.01 |
| Operating profit | 11 | 6 | 7 | 6.80 | 6.17 | 5.99 |
| OPM | 16.0% | 9.0% | 10.0% | 10.4% | 7.9% | 6.4% |
| Interest | 1 | 2 | 1 | 2.47 | 2.53 | 3.08 |
| Depreciation | 1 | 1 | 1 | 2.28 | 3 | 3.05 |
| Profit before tax | 8 | 6 | 6 | 3.54 | 2.34 | 3.05 |
| Net profit | 6 | 4 | 6 | 1.44 | 2.34 | 1.61 |
Zenith Drugs profit and loss
Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Sales | 78 | 72 | 92 | 114 | 131 | 133.32 | 171.22 |
| Expenses | 71 | 64 | 85 | 104 | 114 | 119.74 | 159.06 |
| Operating profit | 7 | 7 | 7 | 9 | 17 | 13.58 | 12.16 |
| OPM | 9.0% | 10.0% | 8.0% | 8.0% | 13.0% | 10.2% | 7.1% |
| Other income | 0 | 0 | 1 | 1 | 1 | 2.61 | 5.10 |
| Interest | 1 | 1 | 2 | 2 | 3 | 3.71 | 5.61 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2.97 | 6.05 |
| Exceptional and other items | · | · | -1 | · | -1 | · | · |
| Profit before tax | 5 | 5 | 4 | 7 | 13 | 9.26 | 5.39 |
| Tax rate | 40.0% | 40.0% | 25.0% | 28.6% | 23.1% | 22.7% | 26.9% |
| Net profit | 3 | 3 | 3 | 5 | 10 | 7.16 | 3.94 |
| EPS ₹ | · | · | · | · | 5.59 | 4.18 | 2.30 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 9.0% | 0.0% | 0.0% |
The years to FY24 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Zenith Drugs profitability
Margins and returns on capitalLast year the company kept less from each rupee of sales than the year before. It earns a low return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 9.0% | 10.0% | 8.0% | 8.0% | 13.0% | 10.2% | 7.1% |
| Tax rate | 40.0% | 40.0% | 25.0% | 28.6% | 23.1% | 22.7% | 26.9% |
| ROCE | · | 28.0% | 21.5% | 24.1% | 24.5% | 12.7% | 8.9% |
| ROE | · | 38.0% | 27.5% | 33.6% | 25.2% | 10.9% | 5.5% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 9.0% | 0.0% | 0.0% |
Zenith Drugs debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. Its loans are smaller than its own money. Last year the business brought in more cash than it showed as profit. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take about as long to pay as they did in FY24.
Bars below the line are cash going out.
Zenith Drugs balance sheet
At each 31 March · ₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Equity capital | 0.40 | 0.40 | 0.40 | 0.40 | 17 | 17.15 | 17.15 |
| Reserves | 6 | 9 | 12 | 17 | 45 | 52.23 | 56.17 |
| Net worth | 6.40 | 9.40 | 12.40 | 17.40 | 62 | 69.38 | 73.32 |
| Borrowings | 12 | 15 | 19 | 26 | 25 | 48.57 | 55.11 |
| Other liabilities | 25.60 | 22.60 | 37.60 | 54.60 | 48 | 43.53 | 59.09 |
| Total liabilities | 44 | 47 | 69 | 98 | 135 | 161.48 | 187.52 |
| Fixed assets | 6 | 9 | 10 | 12 | 11 | 40.26 | 37.24 |
| Capital work in progress | 3 | 0 | 3 | 0 | 4 | 3 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 35 | 38 | 56 | 86 | 120 | 118.22 | 136.28 |
| Receivables | · | · | · | · | · | 60.58 | 73.35 |
| Inventory | · | · | · | · | · | 39.61 | 42.42 |
| Cash | · | · | · | · | · | 0.26 | 0.26 |
| Trade payables | · | · | · | · | · | 40.18 | 55.59 |
Zenith Drugs cash flow
₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | 3 | -1 | 5 | -5 | -13 | -5.47 | 8.88 |
| Cash from investing | -5 | -2 | -5 | 0 | 26 | -31.41 | -13.72 |
| Cash from financing | 1 | 3 | 1 | 5 | -4 | 28.39 | 4.83 |
| Net cash flow | -1 | 0 | 1 | 0 | 9 | -8.49 | -0.01 |
| Capital spending | · | · | · | · | · | 0 | 13.75 |
Working capital
Days
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 119 | 119 | 128 | 159 | 188 | 166 | 156 |
| Inventory days | 29 | 52 | 96 | 192 | 249 | 277 | 257 |
| Days payable | 155 | 155 | 274 | 413 | 412 | 281 | 337 |
| Cash conversion cycle | -7 | 17 | -50 | -62 | 25 | 163 | 77 |
| Working capital days | 14 | 24 | 16 | 39 | 112 | 91 | 74 |
Zenith Drugs peers and competitors
Listed SME companies in the same industryBy sales, Zenith Drugs is number 5 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Sat Kartar Life | 220 | 12.9 | 201 | 17 | 12.0% | 0.03 |
| Infinium Pharmachem | 471 | 38.7 | 190 | 12.2 | 11.4% | 0.19 |
| Zenith Drugs | 72 | 18.3 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| Median of the 10 others | 187 | 19.1 | 139 | 9.3 | 10.2% | 0.34 |
Zenith Drugs shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Zenith Drugs shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Feb 24 | Mar 24 | Sep 24 | Mar 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|---|---|
| Promoters | 69.98% | 69.98% | 69.98% | 69.98% | 69.98% | 69.98% |
| Foreign investors (FIIs) | 7.40% | 5.81% | 0.42% | 0.06% | - | - |
| Indian institutions (DIIs) | 3.68% | 1.93% | 0.00% | 0.00% | - | - |
| HNIs (over ₹2 lakh each) | 0.00% | 2.01% | 8.09% | 7.30% | 8.01% | 7.44% |
| Small holders (up to ₹2 lakh) | 11.21% | 13.19% | 17.48% | 18.26% | 17.25% | 17.29% |
| Companies and others | 7.73% | 7.08% | 4.03% | 4.40% | 4.76% | 5.29% |
| Number of shareholders | 1,333 | 1,117 | 1,355 | 1,544 | 1,466 | 1,435 |
The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.
Zenith Drugs latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹93 cr (+42%), net profit ₹1.6 cr (+12%) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 69.98%.
Zenith Drugs announcements
28 on record, latest first; each opens the filing on the exchange
- Outcome of Board MeetingHeld on October 13, 2026PDF ↗
- General Updatessecuring a tender awarded by Haryana Medical Services Corporation LimitedPDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 29, 2026PDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Shareholders meetingNotice of Annual General Meeting to be held on September 29, 2026PDF ↗
- Outcome of Board MeetingHeld on September 05, 2026PDF ↗
- Allotment of Securitiesallotment of 1609050 share warrants pursuant to Preferential Issue at its meeting held on August 26, 2026PDF ↗
- Outcome of Board MeetingHeld on August 26, 2026PDF ↗
- Outcome of Board MeetingHeld on August 26, 2026PDF ↗
Zenith Drugs annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Zenith Drugs share split, bonus and dividends
From the corporate actions the company announces on the exchange
- DividendDIVIDEND - RE 0.5 PER SHAREex-date 17 Sept 2024
Checks we ran on Zenith Drugs' data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,71,48,800 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY20 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Zenith Drugs
What does Zenith Drugs do?
Zenith Drugs is an SME company listed on NSE Emerge, in pharmaceuticals & biotechnology.
What is the share price of Zenith Drugs?
₹42 at the close on 17 Nov 2026, from the exchange's daily figures.
What is the market cap of Zenith Drugs?
₹72 cr at the close on 17 Nov 2026, on 1,71,48,800 shares.
What is the P/E of Zenith Drugs?
18.3 times FY26 profit at the close on 17 Nov 2026 (our arithmetic).
What are Zenith Drugs' revenue and profit?
Revenue ₹171 cr and profit after tax ₹4 cr in FY26.
Who are the promoters of Zenith Drugs?
The promoter group; promoters held 69.98% at 31 March 2026.
What was the IPO price of Zenith Drugs?
₹79 a share; it listed on 27 Feb 2024.
What is Zenith Drugs' website?
www.zenithdrugs.com
More SME companies like Zenith Drugs
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Shelter PharmaSHELTER · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹75 cr
- Onyx BiotecONYX · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹68 cr
- Vilin Bio MedVILINBIO · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹78 cr
- Amwill Health CareAMWILL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹89 cr
- Chandra Bhagat PharmaCBPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹50 cr
- Cian HealthcareCHCL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹108 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2024 →
Built from 28 exchange announcements, 6 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.